Melanom – 2nd line
Stadium III oder IV
BRAF oder NRAS mutiert
panRAF Inhibitor + ERK Inhibitor oder MEK Inhibitor oder CDK4 and CDK6 Inhibitor
Novartis CLXH254C12201
NCT04417621
A Randomized, Open-label, Multi-arm, Two-part, Phase II Study to Assess Efficacy and Safety of Multiple LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma
Prof. Reinhard Dummer